# Jemperli Achieves 100% Success in Bowel Cancer Trial, Enhertu Shows Promise for Advanced Breast Cancer



**Immunotherapy Drug Jemperli Achieves 100% Success in Bowel Cancer Trial**

**CHICAGO** – An immunotherapy drug, Jemperli (dostarlimab), has shown a 100% effectiveness rate in a recent trial, according to data presented at the American Society of Clinical Oncology (ASCO) conference. The trial, conducted by Memorial Sloan Kettering Cancer Centre in the US, involved 42 patients with locally advanced mismatch repair deficient (dMMR) rectal cancer. All participants experienced a complete response, showing no evidence of tumors on scans.

The study indicates Jemperli might spare patients from the need for surgery and chemotherapy, offering a non-invasive alternative. This breakthrough builds on the drug's current NHS approval for certain advanced or recurrent womb cancers. GSK, the firm behind Jemperli, expressed optimism about further evaluations in their ongoing AZUR-1 and AZUR-2 registrational studies.

**Enhertu Shows Promise for Advanced Breast Cancer But Faces NHS Access Challenges**

**CHICAGO** – Enhertu (trastuzumab deruxtecan), a drug for HER2-low breast cancer, has demonstrated its capacity to delay tumor progression by over a year, according to results from the Destiny-Breast06 study presented at the ASCO conference. Despite this, the National Institute for Health and Care Excellence (Nice) has not approved the drug for patients in England and Wales.

The trial included 866 women with advanced HER2-low breast cancer, revealing that Enhertu reduced the risk of cancer spreading by 38% compared to standard chemotherapy. However, the treatment has been adopted in Scotland and Northern Ireland. Advocacy groups call for quick regulatory approval, noting that 1,000 women in England and Wales could benefit from the treatment.

**Conclusion**

The promising results from these trials highlight the potential of immunotherapy and targeted treatments in addressing certain cancers, potentially altering current standards in cancer care.